Another finding in our study was that PRS+APOE and PRS−APOE had relatively lower predictability for the conversion of MCI to AD, compared to MRI and amyloid PET biomarkers, which implies a limitation of PRS use in disease stages when abnormalities on MRI and amyloid PET biomarkers have fully developed. This evidence concerns the gene APOE and Alzheimer disease.